175 related articles for article (PubMed ID: 38199914)
1. Positron Emission Tomography/Computed Tomography Transformation of Oncology: Multiple Myeloma.
Murtazaliev S; Rowe SP; Sheikhbahaei S; Werner RA; Sólnes LB
PET Clin; 2024 Apr; 19(2):249-260. PubMed ID: 38199914
[TBL] [Abstract][Full Text] [Related]
2. Positron Emission Tomography (PET) Radiopharmaceuticals in Multiple Myeloma.
Sachpekidis C; Goldschmidt H; Dimitrakopoulou-Strauss A
Molecules; 2019 Dec; 25(1):. PubMed ID: 31905752
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the diagnostic performance and impact on management of 18F-FDG PET/CT and whole-body MRI in multiple myeloma.
Westerland O; Amlani A; Kelly-Morland C; Fraczek M; Bailey K; Gleeson M; El-Najjar I; Streetly M; Bassett P; Cook GJR; Goh V;
Eur J Nucl Med Mol Imaging; 2021 Jul; 48(8):2558-2565. PubMed ID: 33469686
[TBL] [Abstract][Full Text] [Related]
4. Correlation Between Baseline 18F-FDG PET/CT Findings and CD38- and CD138-Expressing Myeloma Cells in Bone Marrow and Clinical Parameters in Patients with Multiple Myeloma.
Cengiz A; Arda HÜ; Döğer F; Yavaşoğlu İ; Yürekli Y; Bolaman AZ
Turk J Haematol; 2018 Aug; 35(3):175-180. PubMed ID: 29806594
[TBL] [Abstract][Full Text] [Related]
5. Role of FDG PET in the staging of multiple myeloma.
Vicentini JRT; Bredella MA
Skeletal Radiol; 2022 Jan; 51(1):31-41. PubMed ID: 33813607
[No Abstract] [Full Text] [Related]
6. Overview and recent advances in PET/CT imaging in lymphoma and multiple myeloma.
Zanoni L; Mattana F; Calabrò D; Paccagnella A; Broccoli A; Nanni C; Fanti S
Eur J Radiol; 2021 Aug; 141():109793. PubMed ID: 34148014
[TBL] [Abstract][Full Text] [Related]
7. Imaging CXCR4 receptors expression for staging multiple myeloma by using
Shekhawat AS; Singh B; Malhotra P; Watts A; Basher R; Kaur H; Hooda M; Radotra BD
Br J Radiol; 2022 Aug; 95(1136):20211272. PubMed ID: 35731811
[TBL] [Abstract][Full Text] [Related]
8.
Hemrom A; Tupalli A; Alavi A; Kumar R
PET Clin; 2022 Jul; 17(3):415-430. PubMed ID: 35717100
[TBL] [Abstract][Full Text] [Related]
9. 2-deoxy-2[18F]fluoro-D-glucose positron emission tomography-computed tomography in rheumatological diseases.
Subesinghe M; Bhuva S; Arumalla N; Cope A; D'Cruz D; Subesinghe S
Rheumatology (Oxford); 2022 May; 61(5):1769-1782. PubMed ID: 34463703
[TBL] [Abstract][Full Text] [Related]
10. Role of
Cavo M; Terpos E; Nanni C; Moreau P; Lentzsch S; Zweegman S; Hillengass J; Engelhardt M; Usmani SZ; Vesole DH; San-Miguel J; Kumar SK; Richardson PG; Mikhael JR; da Costa FL; Dimopoulos MA; Zingaretti C; Abildgaard N; Goldschmidt H; Orlowski RZ; Chng WJ; Einsele H; Lonial S; Barlogie B; Anderson KC; Rajkumar SV; Durie BGM; Zamagni E
Lancet Oncol; 2017 Apr; 18(4):e206-e217. PubMed ID: 28368259
[TBL] [Abstract][Full Text] [Related]
11. 18F-fluorocholine versus 18F-fluorodeoxyglucose for PET/CT imaging in patients with suspected relapsing or progressive multiple myeloma: a pilot study.
Cassou-Mounat T; Balogova S; Nataf V; Calzada M; Huchet V; Kerrou K; Devaux JY; Mohty M; Talbot JN; Garderet L
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1995-2004. PubMed ID: 27121691
[TBL] [Abstract][Full Text] [Related]
12. PET/Computed Tomography Transformation of Oncology: Immunotherapy Assessment.
Ghodsi A; Hicks RJ; Iravani A
PET Clin; 2024 Apr; 19(2):291-306. PubMed ID: 38199917
[TBL] [Abstract][Full Text] [Related]
13. ¹⁸F-fluoro-deoxyglucose positron emission tomography in assessment of myeloma-related bone disease: a systematic review.
van Lammeren-Venema D; Regelink JC; Riphagen II; Zweegman S; Hoekstra OS; Zijlstra JM
Cancer; 2012 Apr; 118(8):1971-81. PubMed ID: 21887677
[TBL] [Abstract][Full Text] [Related]
14. Present and future role of FDG-PET/CT imaging in the management of breast cancer.
Kitajima K; Miyoshi Y
Jpn J Radiol; 2016 Mar; 34(3):167-80. PubMed ID: 26733340
[TBL] [Abstract][Full Text] [Related]
15. A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma.
Zamagni E; Nanni C; Patriarca F; Englaro E; Castellucci P; Geatti O; Tosi P; Tacchetti P; Cangini D; Perrone G; Ceccolini M; Brioli A; Buttignol S; Fanin R; Salizzoni E; Baccarani M; Fanti S; Cavo M
Haematologica; 2007 Jan; 92(1):50-5. PubMed ID: 17229635
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic value of WB-DWI versus
Zhang B; Zhang L; Bian B; Lin F; Zhu Z; Wang J
Indian J Cancer; 2023; 60(3):303-309. PubMed ID: 37787189
[TBL] [Abstract][Full Text] [Related]
17. Prospective comparison of 18-FDG PET/CT and whole-body diffusion-weighted MRI in the assessment of multiple myeloma.
Mesguich C; Hulin C; Latrabe V; Lascaux A; Bordenave L; Hindié E; Marit G
Ann Hematol; 2020 Dec; 99(12):2869-2880. PubMed ID: 32951093
[TBL] [Abstract][Full Text] [Related]
18. [Clinical value of 18F-FDG-PET and 11C-MET-PET in patients with plasma cell malignancy].
Kobayashi M; Yamashita K; Takaori-Kondo A
Nihon Rinsho; 2015 Jan; 73(1):74-9. PubMed ID: 25626308
[TBL] [Abstract][Full Text] [Related]
19. Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe).
Nanni C; Versari A; Chauvie S; Bertone E; Bianchi A; Rensi M; Bellò M; Gallamini A; Patriarca F; Gay F; Gamberi B; Ghedini P; Cavo M; Fanti S; Zamagni E
Eur J Nucl Med Mol Imaging; 2018 May; 45(5):712-719. PubMed ID: 29270787
[TBL] [Abstract][Full Text] [Related]
20. Current and potential applications of positron emission tomography for multiple myeloma and plasma cell disorders.
Ulaner GA; Landgren CO
Best Pract Res Clin Haematol; 2020 Mar; 33(1):101148. PubMed ID: 32139013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
